. The table reports sites of disease at the time of doxycycline treatment, cytogenetics, objective response (OR) in ocular adnexal and systemic lesions and response duration (TTP, time to progression expressed as months; '+' indicates the absence of lymphoma progression after doxycycline) of the six treated patients. Doxycycline tolerability was excellent; only patient 1 interrupted therapy (nausea). OR was considered separately for the primary and systemic lesions since their different bulk (systemic lesions represented >70%, and up to 90%, of the total clinically evident tumor burden in all the cases) and the potentially different biological significance of responses in these sites. When response was defined considering the whole tumor burden, patient 1 achieved a minimal response and patients 3 and 5 a partial response. Patient 6 had stable disease but demanded immediate salvage therapy; patients 2 and 4 experienced progressive disease requiring additional therapy. All patients but one are alive, with a median overall survival of 81 months (7-128 months); the remaining patient died of cardiovascular complications when she was 91 years old. The study conformed to the tenets of the Declaration of Helsinki and written informed consent was obtained from each patient. In the inferior half of the figure, there are two examples of lymphoma regression. Patient 3: contrasted computed tomography (CT) scan of the abdomen shows a conglomerate of histologically confirmed s.c. nodules of MALT lymphoma (A) that displayed a gradual but durable complete regression (B) after doxycycline treatment. Patient 5: contrasted CT scan of the neck shows multiple cervical lymphadenopathies (C; arrows) that displayed a rapid regression with persistence of one small lymph node (D) after doxycycline treatment. LN, lymph nodes; CR, complete remission, PR, partial response; SD, stable disease; PD, progressive disease. disease; patient 3 ( Figure 1A and B) achieved a durable complete regression of systemic lesions, with stable orbit disease; patient 5 ( Figure 1C and D) achieved a partial regression of both primary and systemic lesions. Interphase FISH (Figure 1) showed trisomy/polysomy 3-18 in four patients, but this was not associated with response.
In conclusion, systemic Cp infection is common in advanced stage OAML and could favor dissemination in these malignancies. This is in line with our unpublished experience on 40 consecutive Cp-positive OAML patients, where Cp infection of PBMC was detected in 11% of patients with stage I lymphoma and in 62% of disseminated cases (P = 0.001). Doxycycline is a valid therapeutic alternative in disseminated OAML, mostly in elderly patients (Figure 1 ), but response degree can vary among the lesions, indicating that tumor clones dependent on antigenic stimulation may be heterogeneously distributed. The obscure effect of a disseminated infection like that caused by Cp cannot be easily compared with the effect of the local Helicobacter pylori infection on gastric MALT lymphoma. Moreover, other interfering factors that could explain the heterogeneous response observed in our patients, like prolonged contact with infected household animals resulting in continuous re-infections [5] or concomitant infections, cannot be excluded; for instance, four patients had chronic conjunctivitis and prolonged contact with household cats, while patients 1 and 3 had hepatitis C virus infection. Additional studies are needed to address molecular evidence explaining this heterogeneity and pathogenic implications of the absence of Cp DNA in systemic lesions.
